Stifel on Kymera Therapeutics (KYMR): 'pipeline progress remains an underappreciated long-term drive'
Tweet Send to a Friend
Stifel analyst Alex Thompson reiterated a Buy rating and $114.00 price target on Kymera Therapeutics (NASDAQ: KYMR).The analyst comments "Coming ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
